C AFFEINISM, a diagnosis recently included in the third edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-III),' is characterized by a constellation of affective, sleep, and psychophysiological manifestations.2 Because symptoms of caffeinism might be confounded or masked by simultaneous ingestion of other drugs, it is pertinent to ask whether high consumers of caffeine differ from low or moderate consumers in their use of other psychoactive agents. Few data are currently available to answer this question. Historically, 18th-century physicians suggested that tea and coffee consumption promoted later use of alcohol, opium, and other stimulants.3 Such claims were never proven. In contrast, increased cigarette smoking has been conclusively associated with high caffeine consumption.4-7 Although Greden et al.' noted that a greater proportion of high caffeine consumers reported use of minor tranquilizers when compared with low or moderate caffeine users, few or no studies have described patterns of use for hypnotics, neuroleptics, antidepressants, or lithium among subgroups of caffeine users. The importance of documenting possible interactions between use of caffeine and use of other drugs increased with several recent discoveries. First, caffeine was shown to interact in vitro with a number of neuroleptics to form flaky precipitates and thus possibly impair the efficacy of these agents.8,9 Second, caffeine clinically antagonizes barbiturates" and monoamine oxidase inhibitors (MAOI)." Third, caffeine and caffeine withdrawal have been noted to alter adrenergic and serotonergic transmission, and thus may interfere with expected results from common psychiatric medications.'." Finally, following the exciting discovery that the brain contained specific receptors for benzodiazepines, it was noted that caffeine was a competitive inhibitor of diazepam binding to these brain receptors.'3,'4 Conceivably, competitive interference
Use of selective serotonin reuptake inhibitors continues to increase, as does concern about previously unrecognized, subtle side effects and questions about whether these drugs produce effects on healthy subjects. The authors report novel emotional effects identified by an experienced, psychologically healthy meditator who is a psychiatrist and researcher. On a meditation retreat, the subject identified a specific profile of emotional changes related to sertraline use. In particular, cognitive abilities and the emotions of fear and anger seemed unaffected. However, the emotions of sadness, happiness, rapture, and love were dramatically reduced in intensity and duration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.